Bright Futures Wealth Management LLC. Sells 958 Shares of Pfizer Inc. (NYSE:PFE)

Bright Futures Wealth Management LLC. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 9.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,679 shares of the biopharmaceutical company’s stock after selling 958 shares during the period. Bright Futures Wealth Management LLC.’s holdings in Pfizer were worth $258,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer during the 3rd quarter worth approximately $35,000. Joseph Group Capital Management lifted its stake in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $43,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 0.7 %

PFE opened at $25.64 on Friday. The stock’s fifty day moving average is $26.28 and its two-hundred day moving average is $27.63. The company has a market capitalization of $145.28 billion, a P/E ratio of 18.18, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 EPS. The business’s revenue was up 24.7% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.